Pulmatrix, Inc. (PULM)
- Previous Close
1.8900 - Open
1.9010 - Bid --
- Ask --
- Day's Range
1.9010 - 1.9800 - 52 Week Range
1.5500 - 2.8800 - Volume
3,058 - Avg. Volume
14,411 - Market Cap (intraday)
7.195M - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-2.4200 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
www.pulmatrix.comRecent News: PULM
Performance Overview: PULM
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PULM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PULM
Valuation Measures
Market Cap
6.94M
Enterprise Value
-748.66k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.59
Price/Book (mrq)
0.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-75.73%
Return on Assets (ttm)
-17.70%
Return on Equity (ttm)
-38.45%
Revenue (ttm)
11.68M
Net Income Avi to Common (ttm)
-8.85M
Diluted EPS (ttm)
-2.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
16.3M
Total Debt/Equity (mrq)
45.28%
Levered Free Cash Flow (ttm)
-4.93M